Join Growin Stock Community!

Ultragenyx pharmaceutical inc.RARE.US Overview

US StockHealthcare
(No presentation for RARE)
My Watchlist

Ticker

Value

empty

There is no following symbol in this watchlist.

RARE AI Insights

RARE Overall Performance

RARE AI Analysis & Strategy

AI Strategy

Browsing restrictions can be lifted for a fee.

RARE Recent Performance

-1.39%

Ultragenyx pharmaceutical inc.

0.05%

Avg of Sector

-0.31%

S&P500

RARE PowerScanner

Introduction >>

Power Squeeze

Surfing Trend

1 Day

1 Week

1 Month

RARE Key Information

RARE Financial Forecast

chart

Browsing restrictions can be lifted for a fee.

QuarterlyEPS ForecastQoQMaxMin
2026Q1
2026Q2
2026Q3
2026Q4
2027Q1

RARE Profile

Ultragenyx Pharmaceutical Inc., a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Europe, and internationally. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast growth factor 23 for the treatment of X-linked hypophosphatemia, as well as tumor-induced osteomalacia; Mepsevii, an enzyme replacement therapy for the treatment of children and adults with Mucopolysaccharidosis VII; Dojolvi for treating long-chain fatty acid oxidation disorders; and Evkeeza (evinacumab) for the treatment of homozygous familial hypercholesterolemia. The company's products candidatures include DTX401, an adeno-associated virus 8 (AAV8) gene therapy clinical candidate for the treatment of patients with glycogen storage disease type Ia; DTX301, an AAV8 gene therapy for the treatment of patients with ornithine transcarbamylase; UX143, a human monoclonal antibody for the treatment of osteogenesis imperfecta; GTX-102, an antisense oligonucleotide for the treatment of Angelman syndrome; UX701, for the treatment of Wilson disease; and UX053 for the treatment of glycogen storage disease type III. Ultragenyx Pharmaceutical Inc. has collaboration and license agreement with Kyowa Kirin Co., Ltd.; Saint Louis University; Baylor Research Institute; REGENXBIO Inc.; Bayer Healthcare LLC; GeneTx; Mereo; University of Pennsylvania; Arcturus Therapeutics Holdings Inc., Solid Biosciences Inc.; and Daiichi Sankyo Co., Ltd. Ultragenyx Pharmaceutical Inc. was incorporated in 2010 and is headquartered in Novato, California.

Price of RARE

RARE FAQ

This disclaimer is provided by TradingValley Inc. and includes any messages, news, research, analysis, prices or other information provided by the Company's website, the application "Growin App" and other services provided through the Company's website. It is only general market information for educational and investment decision-making reference, and does not constitute any investment advice. View Growin Disclaimer

RARE Earnings Table

Unit : USD

QTRNon-GAAP EPSEPS YoYEPS Surprise %SalesSales YoYSales Surprise %NPM
Current
2025Q4
2025Q3
2025Q2
2025Q1
METRIC
VALUE
vs. INDUSTRY
EPS (TTM)
-5.95
PE Ratio (TTM)
-
Forward PE
-
PS Ratio (TTM)
3.36
PB Ratio
247.70
Price-to-FCF
-
METRIC
VALUE
vs. INDUSTRY
Gross Margin
83.80%
Net Margin
-85.44%
Revenue Growth (YoY)
20.13%
Profit Growth (YoY)
16.65%
3-Year Revenue Growth
26.11%
3-Year Profit Growth
21.98%
METRIC
VALUE
vs. INDUSTRY
EPS (TTM)
-5.95
PE Ratio (TTM)
-
Forward PE
-
PS Ratio (TTM)
3.36
PB Ratio
247.70
Price-to-FCF
-
Gross Margin
83.80%
Net Margin
-85.44%
Revenue Growth (YoY)
20.13%
Profit Growth (YoY)
16.65%
3-Year Revenue Growth
26.11%
3-Year Profit Growth
21.98%

  • When is RARE's latest earnings report released?

    The most recent financial report for Ultragenyx pharmaceutical inc. (RARE) covers the period of 2025Q4 and was published on 2025/12/31. This report is prepared according to IFRS/US GAAP standards and includes key financial indicators—Revenue, Profitability, Cash Flow, and Capital Structure. This information is essential for investors evaluating RARE's short-term business performance and financial health. For the latest updates on RARE's earnings releases, visit this page regularly.

  • What is the operating profit of RARE?

    According to the latest financial report, Ultragenyx pharmaceutical inc. (RARE) reported an Operating Profit of -113.28M with an Operating Margin of -54.65% this period, representing a growth of 10.26% compared to the same period last year. Operating Profit reflects the company's core business efficiency and cost control, making it a key indicator for evaluating operational strength and profitability.

  • How is RARE's revenue growth?

    In the latest financial report, Ultragenyx pharmaceutical inc. (RARE) announced revenue of 207.28M, with a Year-Over-Year growth rate of 25.72%. Revenue growth can be driven by product mix changes, market share expansion, price adjustments, or international market penetration. Investors should also monitor gross margin and regional revenue distribution for a comprehensive view of growth quality and sustainability.

  • How much debt does RARE have?

    As of the end of the reporting period, Ultragenyx pharmaceutical inc. (RARE) had total debt of 1.25B, with a debt ratio of 0.82. Long-term debt comprises a higher/lower proportion. The level of financial leverage directly impacts the company's capital structure and interest coverage. If debt is high, pay attention to interest expenses and refinancing risks. Conversely, a low-leverage structure indicates greater risk tolerance but potentially less growth flexibility.

  • How much cash does RARE have?

    At the end of the period, Ultragenyx pharmaceutical inc. (RARE) held Total Cash and Cash Equivalents of 421M, accounting for 0.27 of total assets. Both current and quick ratios indicate robust short-term debt repayment ability. High cash reserves typically mean the company has strong liquidity, supporting operational needs, expansion investments, or shareholder returns.

  • Does RARE go with three margins increasing?

    In the latest report, Ultragenyx pharmaceutical inc. (RARE) did not achieve the “three margins increasing” benchmark, with a gross margin of 85.8%%, operating margin of -54.65%%, and net margin of -62%%. This demonstrates limited improvement in profitability, which is a key signal for fundamental analysis. Investors should consider margin trends alongside other financial indicators to assess RARE's profit trajectory and future growth potential.

  • Is RARE's EPS continuing to grow?

    According to the past four quarterly reports, Ultragenyx pharmaceutical inc. (RARE)'s earnings per share (EPS) shows a steady growth trend, with the latest EPS at -1.28. If EPS continues to rise due to revenue growth and cost optimization, it can support P/E valuation recovery and attract long-term investors.

  • What is the FCF of RARE?

    Ultragenyx pharmaceutical inc. (RARE)'s Free Cash Flow (FCF) for the period is -100.77M, calculated as Operating Cash Flow minus Capital Expenditures, representing a fall of 25.71% compared with the previous period. Positive FCF growth provides stable funding for dividends, debt repayment, or strategic acquisitions, and is an important measure of true profitability and shareholder return potential.

  • What are the PEG ratio and PE ratio of RARE?

    The latest valuation data shows Ultragenyx pharmaceutical inc. (RARE) has a Price-To-Earnings (PE) ratio of -3.44 and a Price/Earnings-To-Growth (PEG) ratio of 0.15. A PEG below 1 usually suggests the market is underestimating growth potential, while a PEG above 1 indicates high growth expectations are already priced in. Investors should conduct a comprehensive valuation by considering historical growth, market forecasts, and industry cycles.